Pharmacological inhibition of the MAPK/ERK pathway increases sensitivity to 2-chloro-2′-deoxyadenosine (CdA) in the B-cell leukemia cell line EHEB

Biochemical Pharmacology

Volumn 73, Issue 3, 2007, Pages 351-358

  Smal, Caroline ^a   Lisart, Stéphanie ^a   Maerevoet, Marie ^b   Ferrant, Augustin ^c   Bontemps, Françoise ^a   Van Den Neste, Eric ^a,c  

^a DE DUVE INSTITUTE   (Belgium)

^b Clinique Saint Pierre of Ottignies   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

2 Chloro 2 deoxyadenosine; Caspase 3; Chronic lymphocytic leukemia; EHEB; MAPK ERK pathway; MEK inhibitors

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE; CLADRIBINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; U 0124;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG INDUSTRY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CLADRIBINE; DRUG INTERACTIONS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS;

EID: 33845662313     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.10.012     Document Type: Article

References (33)

1. Cardoen S., Van Den Neste E., Smal C., Rosier J.F., Delacauw A., Ferrant A., et al. Resistance to 2-chloro-2′-deoxyadenosine of the human B-cell leukemia cell line EHEB. Clin Cancer Res 7 (2001) 3559-3566
2. Van Den Neste E., Cardoen S., Offner F., and Bontemps F. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review). Int J Oncol 27 (2005) 1113-1124
3. Cardoen S., Van Den Neste E., Smal C., Rosier J.F., Ferrant A., Van Den Berghe G., et al. Effects of 2-chloro-2′-deoxyadenosine on the cell cycle in the human leukemia EHEB cell line. Nucleos Nucleot Nucl Acids 23 (2004) 1425-1429
4. Platanias L.C. Map kinase signaling pathways and hematologic malignancies. Blood 101 (2003) 4667-4679
5. Maggio S.C., Rosato R.R., Kramer L.B., Dai Y., Rahmani M., Paik D.S., et al. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 64 (2004) 2590-2600
6. Chang F., Steelman L.S., Lee J.T., Shelton J.G., Navolanic P.M., Blalock W.L., et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17 (2003) 1263-1293
7. Milella M., Kornblau S.M., Estrov Z., Carter B.Z., Lapillonne H., Harris D., et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 108 (2001) 851-859
8. Jarvis W.D., Fornari Jr. F.A., Tombes R.M., Erukulla R.K., Bittman R., Schwartz G.K., et al. Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-d-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling. Mol Pharmacol 54 (1998) 844-856
9. Yu C., Wang S., Dent P., and Grant S. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway. Mol Pharmacol 60 (2001) 143-154
10. Dent P., Jarvis W.D., Birrer M.J., Fisher P.B., Schmidt-Ullrich R.K., and Grant S. The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity. Leukemia 12 (1998) 1843-1850
11. Persons D.L., Yazlovitskaya E.M., Cui W., and Pelling J.C. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 5 (1999) 1007-1014
12. Saltman D., Bansal N.S., Ross F.M., Ross J.A., Turner G., and Guy K. Establishment of a karyotypically normal B-chronic lymphocytic leukemia cell line; evidence of leukemic origin by immunoglobulin gene rearrangement. Leuk Res 14 (1990) 381-387
13. Bontemps F., Delacauw A., Cardoen S., Van Den Neste E., and Van Den Berghe G. Metabolism and cytotoxic effects of 2-chloroadenine, the major catabolite of 2-chloro-2′-deoxyadenosine. Biochem Pharmacol 59 (2000) 1237-1243
14. Kaspers G.J., Veerman A.J., Pieters R., Van Zantwijk I., Hahlen K., and Van Wering E.R. Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Leuk Res 19 (1995) 175-181
15. Van Den Neste E., Bontemps F., Delacauw A., Cardoen S., Louviaux I., Scheiff J.M., et al. Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2′-deoxyadenosine. Leukemia 13 (1999) 918-925
16. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
17. English J.M., and Cobb M.H. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 23 (2002) 40-45
18. Pepper C., Thomas A., Hoy T., Milligan D., Bentley P., and Fegan C. The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Blood 101 (2003) 2454-2460
19. Barragan M., Bellosillo B., Campas C., Colomer D., Pons G., and Gil J. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood 99 (2002) 2969-2976
20. Bogner C., Ringshausen I., Schneller F., Fend F., Quintanilla-Martinez L., Hacker G., et al. Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells. Br J Haematol 122 (2003) 260-268
21. Dai Y., Yu C., Singh V., Tang L., Wang Z., McInistry R., et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 61 (2001) 5106-5115
22. Mas V.M., Hernandez H., Plo I., Bezombes C., Maestre N., Quillet-Mary A., et al. Protein kinase Czeta mediated Raf-1/extracellular-regulated kinase activation by daunorubicin. Blood 101 (2003) 1543-1550
23. Jazirehi A.R., Vega M.I., Chatterjee D., Goodglick L., and Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res 64 (2004) 7117-7126
24. Lunghi P., Tabilio A., Dall'Aglio P.P., Ridolo E., Carlo-Stella C., Pelicci P.G., et al. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia 17 (2003) 1783-1793
25. Smal C., Cardoen S., Bertrand L., Delacauw A., Ferrant A., Van Den Bergue A., et al. Activation of deoxycytidine kinase by protein kinase inhibitors and okadaic acid in leukemic cells. Biochem Pharmacol 68 (2004) 95-103
26. Keszler G., Virga S., Spasokoukotskaja T., Bauer P.I., Sasvari-Szekely M., and Staub M. Activation of deoxycytidine kinase by deoxyadenosine: implications in deoxyadenosine-mediated cytotoxicity. Arch Biochem Biophys 436 (2005) 69-77
27. MacKeigan J.P., Collins T.S., and Ting J.P. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 275 (2000) 38953-38956
28. Brantley-Finley C., Lyle C.S., Du L., Goodwin M.E., Hall T., Szwedo D., et al. The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide. Biochem Pharmacol 66 (2003) 459-469
29. Shonai T., Adachi M., Sakata K., Takekawa M., Endo T., Imai K., et al. MEK/ERK pathway protects ionizing radiation-induced loss of mitochondrial membrane potential and cell death in lymphocytic leukemia cells. Cell Death Differ 9 (2002) 963-971
30. Lee Jr. J.T., and McCubrey J.A. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukaemia. Leukemia 16 (2002) 486-507
31. Lorusso P.M., Adjei A.A., Varterasian M., Gadgeel S., Reid J., Mitchell D.Y., et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23 (2005) 5281-5293
32. Kamiguti A.S., Harris R.J., Slupsky J.R., Baker P.K., Cawley J.C., and Zuzel M. Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways. Oncogene 22 (2003) 2272-2284
33. Ringshausen I., Schneller F., Bogner C., Hipp S., Duyster J., Peschel C., et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood 100 (2002) 3741-3748